TransMedics Group, Inc. (TMDX) stock
Close on Nov 17, 2026Market cap $3.26BP/E 24.4Yield 0.00%
Earnings
TransMedics's quarterly results as reported in its earnings releases, with the company's own outlook. Hover a number to see the sentence it came from.
Quarterly results
Revenue and earnings per share from each of TransMedics's earnings releases, newest first
| Quarter | Reported | Revenue | YoY | EPS | Adj. EPS | Source |
|---|---|---|---|---|---|---|
| Q4 FY2026ended Dec 31, 2026 | Feb 23, 2027Expected | – | – | – | – | – |
| Q3 FY2026ended Sep 30, 2026 | Nov 5, 2026after the close | $203.00M | +41.2% | $0.46 | $0.51 | Release |
| Q2 FY2026ended Jun 30, 2026 | Aug 4, 2026during market hours | $189.90M | +20.6% | $0.41 | $0.44 | Release |
| Q1 FY2026ended Mar 31, 2026 | May 5, 2026during market hours | $173.90M | +21.2% | $0.20 | $0.30 | Release |
| Q4 FY2025ended Dec 31, 2025 | Feb 24, 2026during market hours | $160.80M | +32.2% | $2.62 | – | Release |
| Q3 FY2025ended Sep 30, 2025 | Oct 29, 2025during market hours | $143.80M | +32.2% | $0.66 | – | Release |
| Q2 FY2025ended Jun 30, 2025 | Jul 30, 2025during market hours | $157.40M | +37.7% | $0.92 | – | Release |
| Q1 FY2025ended Mar 31, 2025 | May 8, 2025during market hours | $143.50M | +48.1% | $0.70 | – | Release |
| Q4 FY2024ended Dec 31, 2024 | Feb 27, 2025during market hours | $121.60M | +49.8% | $0.19 | – | Release |
| Q3 FY2024ended Sep 30, 2024 | Oct 28, 2024during market hours | $108.80M | +63.9% | $0.12 | – | Release |
| Q2 FY2024ended Jun 30, 2024 | Jul 31, 2024during market hours | $114.30M | +117.7% | $0.35 | – | Release |
| Q1 FY2024ended Mar 31, 2024 | Apr 30, 2024during market hours | $96.90M | +132.9% | $0.35 | – | Release |
| Q4 FY2023ended Dec 31, 2023 | Feb 26, 2024during market hours | $81.20M | +158.6% | $0.12 | – | Release |
| Q3 FY2023ended Sep 30, 2023 | Nov 6, 2023during market hours | $66.40M | +158.4% | -$0.78 | – | Release |
| Q2 FY2023ended Jun 30, 2023 | Aug 3, 2023during market hours | $52.50M | +156.1% | -$0.03 | – | Release |
| Q1 FY2023ended Mar 31, 2023 | May 1, 2023during market hours | $41.60M | +161.6% | -$0.08 | – | Release |
| Q4 FY2022ended Dec 31, 2022 | Feb 22, 2023during market hours | $31.40M | +223.7% | -$0.21 | – | Release |
| Q3 FY2022ended Sep 30, 2022 | Nov 3, 2022during market hours | $25.70M | +375.9% | -$0.25 | – | Release |
| Q2 FY2022ended Jun 30, 2022 | Aug 1, 2022during market hours | $20.50M | – | -$0.41 | – | Release |
| Q1 FY2022ended Mar 31, 2022 | May 3, 2022during market hours | $15.90M | – | -$0.38 | – | Release |
| Q4 FY2021ended Dec 31, 2021 | Feb 23, 2022during market hours | $9.70M | – | -$0.46 | – | Release |
| Q3 FY2021ended Sep 30, 2021 | Nov 9, 2021during market hours | $5.40M | – | -$0.47 | – | Release |
| Q2 FY2021ended Jun 30, 2021 | Aug 5, 2021during market hours | – | – | – | – | Filing |
| Q1 FY2021ended Mar 31, 2021 | May 4, 2021during market hours | – | – | – | – | Filing |
| Q4 FY2020ended Dec 31, 2020 | Mar 2, 2021during market hours | – | – | – | – | Filing |
| Q3 FY2020ended Sep 30, 2020 | Nov 4, 2020during market hours | – | – | – | – | Filing |
Figures as first announced; later restatements appear under Financials. Expected dates are estimated from the company's past reporting pattern.
Current guidance
TransMedics's latest outlook for periods it has not reported yet, compared with what it said before
| Metric | Period | Guidance | Before | Change | Given |
|---|---|---|---|---|---|
| full-year 2026 revenue guidance, excluding PAD Aviationnon-GAAP | FY2026 | $737.00M – $757.00M | – | New | Aug 4, 2026 |
| FY 2026 Revenue (excluding PAD Aviation)non-GAAP | FY2026 | $750.00M – $760.00M | – | New | Nov 5, 2026 |
| FY 2026 Revenue (including PAD Aviation)GAAP | FY2026 | $764.00M – $774.00M | – | New | Nov 5, 2026 |
| revenue guidance | FY2026 | $727.00M – $757.00M | $727.00M – $757.00M | Reaffirmed | May 5, 2026 |
Guidance vs results
The last range TransMedics gave before each report, against the figure it then reported. Full years add up the four quarters.
| Period | Metric | Guidance | Actual | Result |
|---|---|---|---|---|
| FY2025 | Revenue | $595.00M – $605.00M | $605.50MΣ4Q | Above range |
Guidance history
Every forecast TransMedics put in an earnings release, newest first
| Given | Metric | Period | Guidance | Change |
|---|---|---|---|---|
| Nov 5, 2026 | FY 2026 Revenue (including PAD Aviation) | FY2026 | $764.00M – $774.00M | New |
| Nov 5, 2026 | FY 2026 Revenue (excluding PAD Aviation) | FY2026 | $750.00M – $760.00M | New |
| Aug 4, 2026 | full-year 2026 revenue guidance, excluding PAD Aviation | FY2026 | $737.00M – $757.00M | New |
| May 5, 2026 | revenue guidance | FY2026 | $727.00M – $757.00M | Reaffirmed |
| Feb 24, 2026 | total revenue | FY2026 | $727.00M – $757.00M | New |
| Oct 29, 2025 | revenue guidance | FY2025 | $595.00M – $605.00M | New |
| Jul 30, 2025 | revenue guidance | FY2025 | $585.00M – $605.00M | Raised |
| May 8, 2025 | revenue guidance | FY2025 | $565.00M – $585.00M | Raised |
| Feb 27, 2025 | total revenue growth | FY2025 | +20% – +25% | New |
| Feb 27, 2025 | total revenue | FY2025 | $530.00M – $552.00M | New |
| Oct 28, 2024 | growth | FY2024 | +76% – +84% | New |
| Oct 28, 2024 | revenue | FY2024 | $425.00M – $445.00M | Reaffirmed |
| Jul 31, 2024 | revenue guidance | FY2024 | $425.00M – $445.00M | Raised |
| Apr 30, 2024 | revenue | FY2024 | $390.00M – $400.00M | Raised |
| Feb 26, 2024 | total revenue | FY2024 | $360.00M – $370.00M | New |
| Nov 6, 2023 | revenue guidance | FY2023 | $222.00M – $230.00M | Raised |
| Aug 3, 2023 | revenue | FY2023 | $180.00M – $190.00M | Raised |
| May 1, 2023 | revenue | FY2023 | $160.00M – $170.00M | Raised |
| Feb 22, 2023 | total revenue | FY2023 | $138.00M – $145.00M | New |
| Nov 3, 2022 | revenue | FY2022 | $80.00M – $85.00M | New |
| Aug 1, 2022 | net revenue | FY2022 | $67.00M – $75.00M | Raised |
| May 3, 2022 | net revenue | FY2022 | $59.00M – $65.00M | Raised |
| Feb 23, 2022 | net revenue | FY2022 | $49.00M – $55.00M | New |
| Nov 9, 2021 | net revenue | FY2021 | $27.60M – $28.60M | New |
Read from the company's earnings releases; each figure links to its sentence on hover. “Raised” and “Lowered” compare with the previous range for the same metric and period.
Press releases
Releases TransMedics filed with the SEC as exhibits to Form 8-K or 6-K
- Results
- Update
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Results
- Update
- Results
- Results
- Results
- Results
See a number that looks wrong?